CClinicalTrials.gg
CompletedNCT00680082Updated Dec 2, 2010

Observational Usage Study of Statins in Primary Care in France

An observational study in Healthy, sponsored by AstraZeneca. Completed at 25 sites in China. Per ClinicalTrials.gov, last updated 2010-12-02.

Sponsored by AstraZeneca · Observational

Study type
Observational
Model
Cohort
Time perspective
Cross-sectional
Enrollment
2,100
Sex
All
01

Study summary

To describe the way statins are used in France in primary care, that is to determine patients profile (particularly CV risk factors), to determine the way statins are initiated by general practitioners, to evaluate aftercare and to assess patients treated by rosuvastatin

02

Conditions studied

  • Healthy

Keywords

  • statins
  • rosuvastatin
  • cross sectional study
  • France
  • CV risk factors
03

In context

Lead sponsor

AstraZeneca is the lead sponsor of 3,429 studies on the registry; 270 are open to participants now.

Of its 357 completed or terminated interventional studies of FDA-regulated products, 173 (48%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Probability sample

Study population

Patients recruited by a GP, community sample

Eligibility criteria

Inclusion Criteria:

  • Patients to whom a statin was initiated or switched between 3 and 6 months before consultation
05

Study design

Observational model
Cohort
Time perspective
Cross-sectional
Enrollment
2,100 participants (actual)

Groups and cohorts

  • 1

    Patients to whom a statin was initiated or switched between 3 and 6 months before consultation

06

Study locations

25 sites
  • Research Site
    Hefei, Anhui, China
  • Research Site
    Chongqing, Chongqing, China
  • Research Site
    Fuzhou, Fujian, China
  • Research Site
    Guangzhou, Guangdong, China
  • Research Site
    Shenzhen, Guangdong, China
  • Research Site
    Xiamen, Guangdong, China
  • Research Site
    Zhongshan, Guangdong, China
  • Research Site
    Zhengzhou, Henan, China
  • Research Site
    Wuhan, Hubei, China
  • Research Site
    Changsha, Hunan, China
  • Research Site
    Nanjing, Jiangsu, China
  • Research Site
    Suzhou, Jiangsu, China
  • Research Site
    Wuxi, Jiangsu, China
  • Research Site
    Nanchang, Jiangxi, China
  • Research Site
    Jinan, Shandong, China
  • Research Site
    Qingdao, Shandong, China
  • Research Site
    Shanghai, Shanghai, China
  • Research Site
    Taiyuan, Shanxi, China
  • Research Site
    Xi'an, Shanxi, China
  • Research Site
    Chengdu, Sichuan, China
  • Research Site
    Kunming, Yunnan, China
  • Research Site
    Hangzhou, Zhejiang, China
  • Research Site
    Ningbo, Zhejiang, China
  • Research Site
    Rui'an, Zhejiang, China
  • Research Site
    Wenzhou, Zhejiang, China
07

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Dec 2, 2010, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
08

Registry details

Key details

Study ID
NCT00680082
Lead sponsor
AstraZeneca
First posted
May 19, 2008
Start date
Feb 2008
Primary completion
Jul 2009
Completion
Jul 2009
Last update
Dec 2, 2010

Study contacts

Francois Morand
principal investigator · Cegedim Strategic Data - Boulogne Billancourt - France
Jean Dallongeville
study chair · Institut Pasteur - Inserm U744 - Lille -France

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2010. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion